116 related articles for article (PubMed ID: 22649141)
1. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer.
Sclafani F; Giuseppe G; Mezynksi J; Collins C; Crown J
J Clin Oncol; 2012 Sep; 30(26):e257-9. PubMed ID: 22649141
[No Abstract] [Full Text] [Related]
2. [Reversible posterior leukoencephalopathy syndrome associated to bevacizumab].
Ortiz-Lopez EM; Gonzalez-Nieto JA; Rojas-Marcos I; Blanco-Ollero A
Rev Neurol; 2010 Jul; 51(2):117-8. PubMed ID: 20602317
[No Abstract] [Full Text] [Related]
3. Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab.
Peter S; Hausmann N; Schuster A; Boehm HF
Clin Exp Ophthalmol; 2008; 36(1):94-6. PubMed ID: 18290962
[No Abstract] [Full Text] [Related]
4. Posterior reversible encephalopathy syndrome with bevacizumab.
Lau PC; Paunipagar B
Hong Kong Med J; 2011 Feb; 17(1):80-1. PubMed ID: 21282833
[No Abstract] [Full Text] [Related]
5. Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case.
Koopman M; Muller EW; Punt CJ
Dis Colon Rectum; 2008 Sep; 51(9):1425-6. PubMed ID: 18470563
[No Abstract] [Full Text] [Related]
6. Benign reversible encephalopathy syndrome after bevacizumab therapy for metastatic ovarian cancer.
Sawaya R; Radwan W; Hammoud S
Med Oncol; 2014 Feb; 31(2):831. PubMed ID: 24385223
[No Abstract] [Full Text] [Related]
7. Potential withdrawal of bevacizumab for the treatment of breast cancer.
Jones A; Ellis P
BMJ; 2011 Aug; 343():d4946. PubMed ID: 21816748
[No Abstract] [Full Text] [Related]
8. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
Lou E; Turner S; Sumrall A; Reardon DA; Desjardins A; Peters KB; Sampson JH; Friedman HS; Vredenburgh JJ
J Clin Oncol; 2011 Oct; 29(28):e739-42. PubMed ID: 21900098
[No Abstract] [Full Text] [Related]
9. FDA committee votes to withdraw bevacizumab for breast cancer.
Lenzer J
BMJ; 2011 Jul; 343():d4244. PubMed ID: 21729988
[No Abstract] [Full Text] [Related]
10. Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen.
Bürki F; Badie K; Bartoli P; Bernard P; Montastruc JL; Bagheri H
Br J Clin Pharmacol; 2008 May; 65(5):793-4. PubMed ID: 18279475
[No Abstract] [Full Text] [Related]
11. [Reversible posterior leukoencephalopathy: the guilty list is increasing].
Alaña M; Navarro M; Pascual J
Neurologia; 2008 Mar; 23(2):137; author reply 137-8. PubMed ID: 18322836
[No Abstract] [Full Text] [Related]
12. Retrobulbar optic neuritis in a bevacizumab-treated patient with metastatic breast cancer.
Zhou Y; Zhang Y; Yang X; Fan L; Jiang J
Breast J; 2012 Sep; 18(5):502-3. PubMed ID: 22891618
[No Abstract] [Full Text] [Related]
13. Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient.
Abbas O; Shamseddin A; Temraz S; Haydar A
BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23436889
[TBL] [Abstract][Full Text] [Related]
14. FDA pulls approval for avastin in breast cancer.
Rose S
Cancer Discov; 2011 Dec; 1(7):OF1-2. PubMed ID: 22586694
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment.
Seet RC; Rabinstein AA
QJM; 2012 Jan; 105(1):69-75. PubMed ID: 21865314
[TBL] [Abstract][Full Text] [Related]
16. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
[No Abstract] [Full Text] [Related]
17. Posterior reversible encephalopathy syndrome associated with deoxycoformycin and alemtuzumab.
Cooksley T; Haji-Michael P
J R Coll Physicians Edinb; 2011 Sep; 41(3):215-7. PubMed ID: 21949916
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab recommendation highlights difficulties.
Printz C
Cancer; 2011 Nov; 117(22):5025. PubMed ID: 22052367
[No Abstract] [Full Text] [Related]
19. Lessons from the other side of the Atlantic.
Prescrire Int; 2012 Jun; 21(128):165-6. PubMed ID: 22822597
[TBL] [Abstract][Full Text] [Related]
20. Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer.
Stefanadis C; Synetos A; Tousoulis D; Tsiamis E; Michelongona A; Zagouri F; Bamias A; Dimopoulos MA; Kyvelou S; Kapelakis I; Toutouzas K
Int J Cardiol; 2012 Feb; 154(3):341-4. PubMed ID: 22078988
[No Abstract] [Full Text] [Related]
[Next] [New Search]
